About OtoNexus
OtoNexus is a company based in Seattle (United States) founded in 2010 by Mark Moehring and Caitlin Cameron. OtoNexus has raised $34.79 million across 13 funding rounds from investors including Children's Hospital of Philadelphia, HHS and Mindshift Capital. OtoNexus offers products and services including Ultrasound Otoscope. OtoNexus operates in a competitive market with competitors including 3Shape, CellScope, TympaHealth, Lantos and 3NT Medical, among others.
- Headquarter Seattle, United States
- Founders Mark Moehring, Caitlin Cameron
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Otonexus Medical Technologies Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$34.79 M (USD)
in 13 rounds
-
Latest Funding Round
$12.9 M (USD), Series C
Oct 20, 2022
-
Investors
Children's Hospital of Philadelphia
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OtoNexus
OtoNexus offers a comprehensive portfolio of products and services, including Ultrasound Otoscope.
Detects bacterial middle ear infections quickly and accurately.
People of OtoNexus
Unlock access to complete
Funding Insights of OtoNexus
OtoNexus has successfully raised a total of $34.79M across 13 strategic funding rounds. The most recent funding activity was a Series C round of $12.9 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OtoNexus
OtoNexus has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Children's Hospital of Philadelphia, HHS and Mindshift Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Investments are directed by Keiretsu Capital into multiple sectors.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for OtoNexus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OtoNexus
Investment portfolio details for OtoNexus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OtoNexus
Detailed financials for OtoNexus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Otonexus Comparisons
Peer comparison for OtoNexus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OtoNexus
OtoNexus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 3Shape, CellScope, TympaHealth, Lantos and 3NT Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of 3D ear scanning systems
|
|
| Locked | Locked | Locked |
In-ear visibility is enabled by smartphone-attached otoscope for at-home diagnosis.
|
|
| Locked | Locked | Locked |
Provider of an AI-based hearing health diagnosis device for medical professionals
|
|
| Locked | Locked | Locked |
Offers comprehensive solutions for 3D digital ear canal scanning technology.
|
|
| Locked | Locked | Locked |
Sinusway device for endoscopy of the nasal cavity & paranasal sinuses
|
Detailed competitors of OtoNexus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Otonexus
Complete news archive for OtoNexus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OtoNexus
OtoNexus was founded in 2010 and raised its 1st funding round 2 years after it was founded.
OtoNexus is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Caitlin Cameron is the current CEO of OtoNexus. They have also founded this company.
OtoNexus is a funded company, having raised a total of $34.79M across 13 funding rounds to date.
Developer of an ultrasound device to non-invasively detect middle ear infections or Otitis Media in both children and adults. The doctor points the device at the eardrum, the device then sends an ultrasound signal that detects if fluid is present behind the eardrum, and if so, what type. Currently, doctors often suggest waiting for 24-48 hours to see if the problem resolves before prescribing antibiotics. According to the founder, OtoNexuss handheld doppler ultrasound will eliminate the need to wait.
OtoNexus's top competitors include 3Shape, TympaHealth and 3NT Medical.
OtoNexus offers Ultrasound Otoscope.
OtoNexus has 6 investors. Key investors include Children's Hospital of Philadelphia, HHS, Mindshift Capital, InnovateHer Seattle, and U.S. Food and Drug Administration.